{
    "clinical_study": {
        "@rank": "136285", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ABC"
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ACB"
            }, 
            {
                "arm_group_label": "Sequence 3", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BAC"
            }, 
            {
                "arm_group_label": "Sequence 4", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BCA"
            }, 
            {
                "arm_group_label": "Sequence 5", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CAB"
            }, 
            {
                "arm_group_label": "Sequence 6", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CBA"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being conducted to measure the relative bioavailability of the original\n      gelatin capsule formulation and a new formulation, immediate release (IR) tablet of\n      Afuresertib (GSK2110183). The study will be composed of Screening, Treatment, and Follow-up\n      Periods.   A subject's total time involved in the study will be approximately 9 weeks. The\n      study will enroll approximately 18 healthy volunteers."
        }, 
        "brief_title": "Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Cancer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provided signed written informed consent\n\n          -  Healthy Male or female between 18 and 40 years of age inclusive, at the time the\n             informed consent is obtained.\n\n          -  Body weight >=50 kilograms (kg) and body mass index (BMI) of >=18 and <= 32 kg/meter\n             square (m^2).\n\n          -  A female subject is eligible to participate if she is of (A) Non-childbearing\n             potential defined as pre-menopausal females with a documented tubal ligation or\n             hysterectomy or postmenopausal defined as 12 months of spontaneous amenorrhea (B)\n             Child-bearing potential with negative pregnancy test as determined by serum human\n             chorionic gonadotropin (hCG) test at Screening and prior to dosing, AND: agrees to\n             use one of the acceptable contraception methods\n\n          -  Male subjects with female partners of child-bearing potential must agree to use one\n             of the contraception methods.\n\n          -  Alanine aminotransferase, alkaline phosphatase and bilirubin <=1.5xupper limit of\n             normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated\n             and direct bilirubin <35%).\n\n          -  Based on single or averaged QT interval corrected (QTc) values of triplicate ECGs\n             obtained over a brief recording period: QTcB <450 millisecond (msec); or QTcB <480\n             msec in subjects with Bundle Branch Block.\n\n          -  Able to swallow and retain orally administered study treatment and does not have any\n             clinically significant gastrointestinal (GI) abnormalities that may alter absorption\n             such as malabsorption syndrome or major resection of the stomach and/or bowels.\n\n        Exclusion Criteria:\n\n          -  Current or chronic history of liver disease, or known hepatic or biliary\n             abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).\n\n          -  History of gastroesophageal reflux disease, dyspepsia, peptic ulcer disease,\n             gastrointestinal (GI) bleeding, GI surgery that could affect motility.\n\n          -  History of atrial arrhythmias\n\n          -  History of regular alcohol consumption within 6 months of the study defined as:\n\n        An average weekly intake of >21 units for males or >14 units for females.  One unit is\n        equivalent to 10 grams (g) of alcohol: 270 mL of full strength beer (4.8%), 375 mL of mid\n        strength beer (3.5%), 470 mL of light beer (2.7%), 250 mL pre-mix full strength spirit\n        (5%), 100mL of wine (13.5%) and 30 mL of spirit (40%).\n\n          -  History of sensitivity to any of the study medications, or components thereof or a\n             history of drug or other allergy that, in the opinion of the Investigator or GSK\n             Medical Monitor, contraindicates their participation\n\n          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody\n             result within 3 months of Screening.\n\n          -  Smoking or history or regular use of tobacco- or nicotine-containing products within\n             6 months prior to screening.\n\n          -  A positive drug/alcohol screen at Screening or upon check-in to the clinic on Day -1\n             of each Dosing Period.\n\n          -  A positive test for human immuno virus (HIV) antibody.\n\n          -  Pregnant females as determined by positive serum hCG test at Screening or prior to\n             dosing.\n\n          -  Where participation in the study would result in donation of blood or blood products\n             in excess of 500 mL within a 56 day period.\n\n          -  Lactating females.\n\n          -  The subject has participated in a clinical trial and has received an investigational\n             product within the following time period prior to the first dosing day in the current\n             study: 30 days, 5 half-lives or twice the duration of the biological effect of the\n             investigational product (whichever is longer).\n\n          -  Exposure to more than four new chemical entities within 12 months prior to the first\n             dosing day.\n\n          -  Any serious and/or unstable pre-existing medical, psychiatric disorder or other\n             conditions that could interfere with subject's safety, obtaining informed consent or\n             compliance to the study procedures.\n\n          -  Any prohibited medications or recent consumption of citrus products."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02040480", 
            "org_study_id": "201039"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 3", 
                    "Sequence 6", 
                    "Sequence 2", 
                    "Sequence 5", 
                    "Sequence 4"
                ], 
                "description": "White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration", 
                "intervention_name": "GSK2110183 Gelatin Capsule", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 3", 
                    "Sequence 6", 
                    "Sequence 2", 
                    "Sequence 5", 
                    "Sequence 4"
                ], 
                "description": "White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration", 
                "intervention_name": "GSK2110183 IR Tablet", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "bioavailability", 
            "food effect", 
            "formulation", 
            "GSK2110183", 
            "afuresertib", 
            "AKT inhibitor"
        ], 
        "lastchanged_date": "April 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Randwick", 
                    "country": "Australia", 
                    "state": "New South Wales", 
                    "zip": "2031"
                }, 
                "name": "GSK Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Single Center, Randomized, Open-Label, Sequential, Single Dose, 3-Period Crossover Study to Evaluate the Bioavailability and Food Effect of a Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib, an AKT Inhibitor, in Normal Healthy Volunteers", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Australia: HERC", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "PK parameters include: area under the plasma concentration-time curve from time zero to infinity (AUC [0-infinity]), area under the plasma concentration time curve from time zero to last time of quantifiable concentration (AUC [0-t]), maximum observed plasma concentration (Cmax), and time to Cmax (tmax).", 
            "measure": "Composite of pharmacokinetic (PK) parameters to determine relative bioavailability of afuresertib after administering it as a single dose in an original gelatin capsule in the fasted state and in a newly formulated IR tablet in the fed and fasted state.", 
            "safety_issue": "No", 
            "time_frame": "PK Samples will be collected Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120, and 168 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02040480"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "AEs will be collected from the start of Study Treatment and until the Follow-up contact.", 
                "measure": "Number of subjects with adverse events (AEs).", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 weeks"
            }, 
            {
                "description": "Laboratory parameters include: hematology, clinical chemistry and urinalysis.", 
                "measure": "Clinical laboratory parameter assessment as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 weeks"
            }, 
            {
                "measure": "Concomitant medications review as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 weeks"
            }, 
            {
                "description": "Triplicate 12-lead ECGs will be collected at Screening; in each Dosing Period on Day 1 and Day 3 of Dosing Period; and at Follow-up.", 
                "measure": "Electrocardiogram (ECGs) measurement as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 weeks"
            }, 
            {
                "description": "Vital sign measurements will include systolic and diastolic blood pressure and pulse rate.", 
                "measure": "Vital sign measurement as a measure of safety and tolerability", 
                "safety_issue": "No", 
                "time_frame": "Up to 9 weeks"
            }, 
            {
                "description": "PK parameters include: AUC (0 - infinity), AUC (0 - t), Cmax, and tmax.", 
                "measure": "Composite of PK parameter following single dose administration of IR tablet in fasted state", 
                "safety_issue": "No", 
                "time_frame": "PK Samples will be collected Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120, and 168 hours post-dose"
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}